Should FDA Relax Phase I Percutaneous Valve Trial Enrollment Criteria?

Pivotal clinical trials for percutaneous aortic or mitral valve repair should have two-year follow-up, rather then the one-year preferred by device firms, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD